Topic: cardiac rhythm management
Acutus secured $170 million after acquiring a catheter developer and announcing a slew of new partnerships in arrhythmia treatment and monitoring.
The deal commits LivaNova to paying up to $20 million in indemnity linked to a probe initiated by antitrust officials around 10 days ago.
LivaNova will sell its Cardiac Rhythm Management business to its joint venture partner, MicroPort Scientific.
LivaNova decided to look to offload the $250 million-a-year pacemaker and defibrillator unit after concluding it no longer fits with its strategy.
The FDA cleared a new version of Medtronic's Reveal Linq, which now includes algorithms that ramp up the implant’s accuracy in reporting abnormal heartbeats.